99mTc Radionuclide-labeled and hydrogel-coated BaTiO3 nanocomposites

Basit Öğe Kaydı
dc.authoridOZDEMIR, Semra/0000-0003-1302-9630
dc.contributor.authorEkici, Sema
dc.contributor.authorOzdemir, Semra
dc.contributor.authorPuren, Busra Aydur
dc.date.accessioned2025-01-27T20:46:12Z
dc.date.available2025-01-27T20:46:12Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThe current developments such as improving of radionuclides and drug carriers in nuclear medicine has been utilized for cancer diagnosis, prevention and treatment, in other words in theranostics. In radionuclide-based imaging, radionuclides can be conjugated to the nanoparticle and directed to the targeted tissue. Inorganic nanoparticles are capable of imaging and treatment of tumors and have demonstrated unique physicochemical and biological properties. In present study, m-BaTiO3 nanocomposites were prepared by coating biocompatible and nanosized BaTiO3 particles (tra-BaTiO3) with poly (3-acrylamidopropyl) trimethyl-ammonium chloride (pAPTMACl) ionic hydrogel. The prepared m-BaTiO3 nanocomposites were then modified with (TcO4-)-Tc-99m selected as radionuclide and 8-hydroxy-7-iodo-5-quinoline sulfonic acid (SQ) which is a drug used in the treatment of cancer, to form m-BaTiO3-(TcO4-)-Tc-99m and m-BaTiO3-SQ radiopharmaceutical nanocomposites, respectively. The characterizations of prepared nanoparticles were carried out with ATR-linked FT-IR and Raman spectroscopy, DLS, zeta potential, TEM, SEM, SEM-Element Mapping analyzes. Radiolabeling studies of m-BaTiO3 nano- composites were monitored with a radionuclide dose calibrator. The suspension stability of tra-BaTiO3 nano-particles was increased after the conjugation of (TcO4-)-Tc-99m and SQ molecules. Particle size values ranking found as; m-BaTiO3-(TcO4-)-Tc-99m < m-BaTiO3-SQ < m-BaTiO3 < tra-BaTiO3. Zeta potential values were measured as -9.80 +/- 1.12 mV,-7.54 +/- 4.46 mV, -21.30 +/- 0.32 mV, -25.60 +/- 0.35 mV for tra-BaTiO3 , m-BaTiO3 , m-BaTiO3-(TcO4-)-Tc-99m, m-BaTiO3-SQ, respectively. The amount of (99m) TcO4- attached to the tra-BaTiO3 nanoparticles increased threefold, after coating with the hydrogel. It was observed that 76 % of SQ drug molecules loaded onto m-BaTiO3-SQ nanocomposites was released within 10 h. Herein, we highlighted the design of BaTiO3 nano-particles with biocompatible and flexible pAPTMACl hydrogel, (99m) Tc radionuclide, and SQ cancer drug for using of radiopharmaceuticals in cancer imaging and radiotherapy in order to be a pioneer study for our researches in the future.
dc.description.sponsorshipScientific Projects Commission of Canakkale Onsekiz Mart University [FHD-2021/3695]
dc.description.sponsorshipFunding This research was supported by the Scientific Projects Commission of Canakkale Onsekiz Mart University, FHD-2021/3695.
dc.identifier.doi10.1016/j.jddst.2024.106028
dc.identifier.issn1773-2247
dc.identifier.issn2588-8943
dc.identifier.scopus2-s2.0-85200550004
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.jddst.2024.106028
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24835
dc.identifier.volume100
dc.identifier.wosWOS:001292038000001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Drug Delivery Science and Technology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectRadionuclide-labeled nanoparticles
dc.subjectNanoradiopharmaceutics
dc.subjectCancer
dc.subjectDrug release
dc.subjectBaTiO(3)Nanocomposites
dc.subject(TcO4-)-Tc-99m
dc.subjectRadionuclide-labeled nanoparticles
dc.subjectNanoradiopharmaceutics
dc.subjectCancer
dc.subjectDrug release
dc.title99mTc Radionuclide-labeled and hydrogel-coated BaTiO3 nanocomposites
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu